Heberprot-P is a drug developed by Genetic Engineering and Biotechnology Center located in Cuba, for treatment of severe diabetic foot ulcer. Its main component is epidermal growth factor (EGF) and it is applied parenterally (intralesional injection directly into the wound). About 160.000 diabetic foot ulcer patients were treated with Heberprot-P and the success of eliminating the amputation risk was seen in 75% of the patients.

In diabetic patients, growth factor, particularly epidermal growth factor receptor (EGF) density decreases. EGF is an important growth factor which regulates the cell growth and cell increase by binding to epidermal growth factor receptors (EGFR). Once EGF decreases, wound healing significantly decreases ad as a result, amputation procedure may be required. When Heberprot-P is applied, healing process duration increases continuously and progressively.

Heberprot-P is applied for the patients whose disease course is poor, chronic non-healing wounds and patients who do not respond to the traditional treatment methods.